Risk of carcinogenesis in the biliary epithelium of children with congenital biliary dilatation through epigenetic and genetic regulation.
Adult
Aged
Biliary Tract Neoplasms
/ etiology
Child
Child, Preschool
Choledochal Cyst
/ complications
Epithelium
/ metabolism
Female
Gallbladder
/ metabolism
Gene Expression Regulation, Neoplastic
/ genetics
Histone Deacetylases
/ genetics
Humans
Infant
Ki-67 Antigen
/ genetics
Male
Middle Aged
Pancreaticobiliary Maljunction
/ surgery
Proto-Oncogene Proteins p21(ras)
/ genetics
Risk
Tumor Suppressor Protein p53
/ genetics
Carcinogenesis
Congenital biliary dilatation
Epigenetic regulation
Genetic regulation
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
25
01
2021
accepted:
01
05
2021
pubmed:
17
6
2021
medline:
2
2
2022
entrez:
16
6
2021
Statut:
ppublish
Résumé
Congenital biliary dilatation (CBD), defined as pancreaticobiliary maljunction (PBM) with biliary dilatation, is a high risk factor for biliary tract cancer (BTC). KRAS and p53 mutations reportedly affect this process, but the mechanisms are unclear, as is the likelihood of BTC later in life in children with CBD. We investigated potential carcinogenetic pathways in children with CBD compared with adults. The subjects of this study were nine children with CBD and 13 adults with PBM (10 dilated, 3 non-dilated) without BTC who underwent extrahepatic bile duct resections, as well as four control patients who underwent pancreaticoduodenectomy for non-biliary cancer. We evaluated expressions of Ki-67, KRAS, p53, histone deacetylase (HDAC) and activation-induced cytidine deaminase (AID) in the biliary tract epithelium immunohistochemically. The Ki-67 labeling index (LI) and expressions of KRAS, p53, HDAC, and AID in the gallbladder epithelium were significantly higher or tended to be higher in both the children with CBD and the adults with PBM than in the controls. BTC may develop later in children with CBD and in adults with PBM, via HDAC and AID expression and through epigenetic and genetic regulation.
Identifiants
pubmed: 34132887
doi: 10.1007/s00595-021-02325-2
pii: 10.1007/s00595-021-02325-2
doi:
Substances chimiques
KRAS protein, human
0
Ki-67 Antigen
0
Tumor Suppressor Protein p53
0
Histone Deacetylases
EC 3.5.1.98
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-223Informations de copyright
© 2021. Springer Nature Singapore Pte Ltd.
Références
Tashiro S, Imaizumi T, Ohkawa H, Okada A, Katoh T, Kawaharada Y, et al. Pancreaticobiliary maljunction: retrospective and nationwide survey in Japan. J Hepatobiliary Pancreat Surg. 2003;10(5):345–51.
pubmed: 14598134
Tsuchida A, Itoi T, Aoki T, Koyanagi Y. Carcinogenetic process in gallbladder mucosa with pancreaticobiliary maljunction. Oncol Rep. 2003;10(6):1693–9.
pubmed: 14534681
Funabiki T, Matsubara T, Miyakawa S, Ishihara S. Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy. Langenbecks Arch Surg. 2009;394(1):159–69.
pubmed: 18500533
Tanno S, Obara T, Fujii T, Mizukami Y, Shudo R, Nishino N, et al. Proliferative potential and k-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer. 1998;83(2):267–75.
pubmed: 9669809
Nagai M, Watanabe M, Iwase T, Yamao K, Isaji S. Clinical and genetic analysis of noncancerous and cancerous biliary epithelium in patients with pancreaticobiliary maljunction. World J Surg. 2002;26(1):91–8.
pubmed: 11898040
Matsubara T, Sakurai Y, Zhi L-Z, Miura H, Ochiai M, Funabiki T. K-ras and p-53 gene mutations in noncancerous biliary lesions of patients with pancreatico biliary maljunction. J Hepatobiliary Pancreat Surg. 2002;9(3):312–21.
pubmed: 12353142
Kamisawa T, Funata N, Hayashi Y, Egawa N, Nakajima H, Tsuruta K, et al. Pathologic changes in the non-carcinomatous epithelium of the gallbladder in patients with a relatively long common channel. Gastrointest Endosc. 2004;60(1):56–60.
pubmed: 15229426
Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10(1):32–42.
pubmed: 19065135
pmcid: 3215088
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51.
pubmed: 16397526
Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420–32.
pubmed: 17694083
Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun. 2001;287(3):705–13.
pubmed: 11563853
pmcid: 11563853
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5(5):455–63.
pubmed: 15144953
Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391(6669):811–4.
pubmed: 9486654
Miyatani T, Kurita N, Mikami C, Kashihara H, Higashijima J, Yoshikawa K, et al. Malignant potential of Barrett’s esophagus: special reference to HDAC-1 and MTA-1 expression. Hepatogastroenterology. 2011;58(106):472–6.
pubmed: 21661415
Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424(6944):94–8.
pubmed: 12808465
pmcid: 1350966
Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol. 2002;20:165–96.
pubmed: 11861601
Wedekind JE, Dance GS, Sowden MP, Smith HC. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 2003;19(4):207–16.
pubmed: 12683974
Cascalho M. Advantages and disadvantages of cytidine deamination. J Immunol. 2004;172(11):6513–8.
pubmed: 15153462
Kinoshita K, Nonaka T. The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond. Int J Hematol. 2006;83(3):201–7.
pubmed: 16720548
Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13(4):470–6.
pubmed: 17401375
Li M, Liu W, Zhu YF, Chen YL, Zhang BZ, Wang R. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer. Acta Oncol. 2006;45(8):1115–9.
pubmed: 17118848
Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, et al. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med. 2011;40(9):706–14.
pubmed: 21457345
Nakanishi Y, Kondo S, Wakisaka N, Tsuji A, Endo K, Murono S, et al. Role of activation-induced cytidine deaminase in the development of oral squamous cell carcinoma. PLoS ONE. 2013;8(4):e62066.
pubmed: 23634222
pmcid: 3636261
Gonzalez-Angulo AM, Sneige N, Buzdar AU, Valero V, Kau SW, Broglio K, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 2004;10(18 Pt 1):6215–21.
pubmed: 15448010
Kato T, Matsuda K, Kayaba H, Enomoto S, Hebiguchi T, Koyama K, et al. Pathology of anomalous junction of the pancreaticobiliary ductal system: mutagenicity of the contents of the biliary tract and nuclear atypia of the biliary epithelium. Keio J Med. 1989;38(2):167–76.
pubmed: 2779060
Kamisawa T, Kurata M, Honda G, Tsuruta K, Okamoto A. Biliopancreatic reflux-pathophysiology and clinical implications. J Hepatobiliary Pancreat Surg. 2009;16(1):19–24.
pubmed: 19110654
Shimada K, Yanagisawa J, Nakayama F. Increased lysophosphatidylcholine and pancreatic enzyme content in bile of patients with anomalous pancreaticobiliary ductal junction. Hepatology. 1991;13(3):438–44.
pubmed: 1999314
Tsuchida A, Itoi T. Carcinogenesis and chemoprevention of biliary tract cancer in pancreaticobiliary maljunction. World J Gastrointest Oncol. 2010;2(3):130–5.
pubmed: 21160820
pmcid: 2999175
Kamisawa T, Kuruma S, Chiba K, Tabata T, Koizumi S, Kikuyama M. Biliary carcinogenesis in pancreaticobiliary maljunction. J Gastroenterol. 2017;52(2):158–63.
pubmed: 27704265
Morine Y, Shimada M, Takamatsu H, Araida T, Endo I, Kubota M, et al. Clinical features of pancreaticobiliary maljunction: update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci. 2013;20(5):472–80.
pubmed: 23579999
Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer. 1996;77(3):452–8.
pubmed: 8630951
Singh MK, Chetri K, Pandey UB, Kapoor VK, Mittal B, Choudhuri G. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19(8):916–21.
pubmed: 15242496
Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder: the impact of chronic inflammation and gallstones. Langenbecks Arch Surg. 2001;386(3):224–9.
pubmed: 11382326
Tomono H, Nimura Y, Aono K, Nakashima I, Iwamoto T, Nakashima N. Point mutations of the c-Ki-ras gene in carcinoma and atypical epithelium associated with congenital biliary dilatation. Am J Gastroenterol. 1996;91(6):1211–4.
pubmed: 8651173
Matsubara T, Funabiki T, Jinno O, Sakurai Y, Hasegawa S, Imazu H, et al. p53 gene mutations and overexpression of p53 product in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg. 1999;6(3):286–93.
pubmed: 10526065
Wistuba II, Gazdar AF. Gallbladder cancer: lessens from rare tumour. Nat Rev Cancer. 2004;4(9):695–706.
pubmed: 15343276
Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–76.
pubmed: 19103471
Shukla S, Khan S, Kumar S, Sinha S, Farhan M, Bora HK, et al. Cucurbitacin B alters the expression of tumor-related genes by epigenetic modifications in NSCLC and inhibits NNK-induced lung tumorigenesis. Cancer Prev Res (Phila). 2015;8(6):552–62.
Tong X, Yin L, Giardina C. Butylrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem Biophys Res Commun. 2004;317(2):463–71.
pubmed: 15063780
Biran A, Brownstein M, Haklai R, Kloog Y. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer. 2011;128(3):691–701.
pubmed: 20473860
Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in humancancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26(3):215–27.
pubmed: 19116762
Søreide K, Søreide JA. Bile duct cyst as precursor to biliary tract cancer. Ann Surg Oncol. 2007;14(3):1200–11.
pubmed: 17187167
Chaudhuri J, Alt FW. Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol. 2004;4(7):541–52.
pubmed: 15229473
Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5):553–63.
pubmed: 11007474
Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T, et al. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology. 2008;135(3):889–98.
pubmed: 18691581
Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology. 2008;47(3):888–96.
pubmed: 18306229
Morita S, Matsumoto Y, Okuyama S, Ono K, Kitamura Y, Tomori A, et al. Bile acid-induced expression of activationinduced cytidine deaminase during the development of Barrett’s oesophageal adenocarcinoma. Carcinogenesis. 2011;32(11):1706–12.
pubmed: 21890457
Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, et al. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer. 2007;120(3):469–76.
pubmed: 17066440
Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, et al. Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer. 2008;123(12):2735–40.
pubmed: 18781563
Ono S, Tokiwa K, Iwai N. Cellular activity in the gallbladder of children with anomalous arrangement of the pancreaticobiliary duct. J pediatr surg. 1999;34(6):962–6.
pubmed: 10392914
Saikusa N, Naito S, Iinuma Y, Ohtani T, Yokoyama N, Nitta K. Invasive cholangiocarcinoma identified in congenital biliary dilatation in a 3-year-old boy. J Pediatr Surg. 2009;44(11):2202–5.
pubmed: 19944233
Nakamura H, Katayose Y, Rikiyama T, Onogawa T, Yamamoto K, Yoshida H, et al. Advanced bile duct carcinoma in a 15-year-old patient with pancreaticobiliary maljunction and congenital biliary cystic disease. J Hepatobiliary Pancreat Surg. 2008;15(5):554–9.
pubmed: 18836813
Tanaka S, Kubota M, Yagi M, Okuyama N, Ohtaki M, Yamazaki S, et al. An 11-year-old male patient demonstrating cholangiocarcinoma associated with congenital biliary dilatation. J Pediatr Surg. 2006;41(1):e15–9.
pubmed: 16410082